NCT06929897

Brief Summary

To date, no optimal treatment has been established to improve outcomes in patients with persistent atrial fibrillation. The safety and efficacy of pulsed-field ablation (PFA) have been demonstrated in several studies, and its clinical application is expanding. \- In patients with persistent atrial fibrillation, can the addition of posterior wall isolation (PWI) following pulmonary vein isolation (PVI) using PFA reduce recurrence? Participants will:

  • Undergo either PVI alone or PVI with additional left atrial posterior wall isolation (PWI)
  • Visit the clinic to assess for recurrence of atrial tachyarrhythmias

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
214

participants targeted

Target at P75+ for not_applicable

Timeline
17mo left

Started May 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress42%
May 2025Oct 2027

First Submitted

Initial submission to the registry

March 13, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 16, 2025

Completed
15 days until next milestone

Study Start

First participant enrolled

May 1, 2025

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2027

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2027

Last Updated

April 16, 2025

Status Verified

April 1, 2025

Enrollment Period

2 years

First QC Date

March 13, 2025

Last Update Submit

April 8, 2025

Conditions

Keywords

pulsed field ablationcatheter ablationposterior wall isolationatrial fibrillation

Outcome Measures

Primary Outcomes (1)

  • Recurrence of atrial tachyarrhythmia

    Clinical recurrence rate of atrial fibrillation within one year after the procedure.

    Within one year from the time of enrollment, excluding the first three months after the procedure

Secondary Outcomes (5)

  • Peri-procedural complication

    Within one year from the time of enrollment

  • Total procedure time

    Periprocedural

  • Length of hospital stay

    Within one year from the time of enrollment

  • patient satisfaction

    Within one year from the time of enrollment

  • Atrial fibrillation burden

    Within one year from the time of enrollment

Study Arms (2)

Additional Left Atrial Posterior Wall Ablation Group

ACTIVE COMPARATOR

After pulmonary vein isolation, electrical isolation of the left atrial posterior wall is performed using a pulsed-field ablation catheter with EGM-guided ablation.

Procedure: Pulmonary Vein IsolationProcedure: Additional Left Atrial Posterior Wall Ablation

Pulmonary Vein Isolation (PVI) only Group

PLACEBO COMPARATOR

Electrical isolation of all four pulmonary veins is performed using a pulsed-field ablation catheter.

Procedure: Pulmonary Vein IsolationProcedure: Non-PV trigger test

Interventions

1. Pulmonary vein isolation (PVI) is performed as the primary procedure. 2. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group. 3. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization.

Also known as: PVI
Additional Left Atrial Posterior Wall Ablation GroupPulmonary Vein Isolation (PVI) only Group

1. Additional left atrial posterior wall ablation is performed. 2. Complete electrical isolation of the entire left atrial posterior wall is confirmed (posterior box lesion isolation must be achieved). 3. Post-procedural rhythm monitoring follows the study protocol.

Also known as: Posterior box isolation
Additional Left Atrial Posterior Wall Ablation Group

1. If atrial fibrillation triggers are identified with isoproterenol infusion, additional focal ablation is performed. 2. Post-procedural rhythm monitoring follows the study protocol.

Pulmonary Vein Isolation (PVI) only Group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients eligible for catheter ablation according to existing clinical guidelines
  • Those without clinically significant structural heart disease (e.g., severe mitral regurgitation)
  • Those without contraindications to anticoagulation therapy

You may not qualify if:

  • Atrial fibrillation associated with severe congenital heart disease or structural heart disease
  • Patients with contraindications to general anesthesia or sedation for the procedure
  • History of prior cardiac surgery (e.g., Maze procedure, coronary artery bypass grafting)
  • History of atrial fibrillation catheter ablation within the past 12 months
  • Patients with severe left ventricular dysfunction (left ventricular ejection fraction \<30%)
  • Patients with active internal bleeding
  • Patients with contraindications to anticoagulation therapy and antiarrhythmic drugs
  • Valvular atrial fibrillation (e.g., mitral stenosis \> grade 2, mechanical valve, prior mitral valve repair)
  • Patients with severe comorbid conditions
  • Patients with an expected survival of less than one year
  • Patients with drug or alcohol addiction
  • Pregnant or breastfeeding women
  • Any other conditions deemed by the investigator to make the patient unsuitable for study participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ewha Womans University Mokdong Hospitoal

Seoul, South Korea

Location

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Junbeom Park, M.D., Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Pulmonary vein isolation (PVI) is performed using pulsed-field ablation. Afterward, electrical cardioversion is performed to restore normal sinus rhythm. Patients who successfully convert to sinus rhythm are then randomly assigned to either the PVI-only group or the PVI with additional left atrial posterior wall isolation group. 1. Patients requiring catheter ablation for persistent atrial fibrillation (AF). 2. AF ablation is performed while maintaining anticoagulation therapy. 3. Pulmonary vein isolation (PVI) is performed as the primary procedure. 4. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group. 5. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 13, 2025

First Posted

April 16, 2025

Study Start

May 1, 2025

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

October 1, 2027

Last Updated

April 16, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Individual participant data (IPD) will not be shared due to concerns regarding patient confidentiality and the lack of specific consent for data sharing obtained during the study enrollment process.

Locations